Short answer
VERACYTE, INC. (VCYT) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). New C-suite role: Dr. Kevin Haas (age 40) appointed Chief Development and Technology Officer, effective March 24, 2026.
VERACYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- New C-suite role: Dr. Kevin Haas (age 40) appointed Chief Development and Technology Officer, effective March 24, 2026
- Recruited from Myriad Genetics (MYGN) where he served as CTO since 2021, bringing deep genomics/bioinformatics expertise directly relevant to VCYT's diagnostic platform
- Base salary $500,000 with 55% target bonus, implying total cash target of ~$775,000
- Equity package totals $3,000,000 target value: $1.5M in RSUs (4-year vest) and $1.5M in performance-based RSUs tied to Compensation Committee objectives
- New dedicated CDT Officer role signals strategic prioritization of technology and R&D development as a growth lever
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other VERACYTE, INC. 8-K filings
Get the next VCYT 8-K as it lands
Follow VCYT for push alerts, or ask the research agent what this filing means.